Match!

NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments

Published on Mar 1, 2016in Lancet Oncology35.39
· DOI :10.1016/S1470-2045(16)00061-9
Caroline J Hall2
Estimated H-index: 2
(National Institute for Health and Care Excellence),
Sally Doss3
Estimated H-index: 3
(National Institute for Health and Care Excellence)
+ 2 AuthorsAndrew Stevens30
Estimated H-index: 30
(National Institute for Health and Care Excellence)
Cite
  • References (2)
  • Citations (1)
Cite
References2
Newest
Published on Oct 1, 2014in Lancet Oncology35.39
Jesús F. San-Miguel102
Estimated H-index: 102
(University of Navarra),
Vânia Tietsche de Moraes Hungria3
Estimated H-index: 3
+ 42 AuthorsNoppadol Siritanaratkul19
Estimated H-index: 19
(Siriraj Hospital)
Summary Background Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone. We aimed to compare panobinostat, bortezomib, and dexamethasone with placebo, bortezomib, and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. Methods PANORAMA1 is a multicentre, randomised, placebo-controlled, double-blind phase 3 trial of patients with relapsed or relapse...
Published on Feb 1, 2013in Supportive Care in Cancer2.75
S. Acaster1
Estimated H-index: 1
,
Sabine Gaugris3
Estimated H-index: 3
(Janssen-Cilag)
+ 2 AuthorsA. J. Lloyd1
Estimated H-index: 1
Background While the impact of various treatments on myeloma patients’ health-related quality of life (HRQL) has been reported, the impact of a treatment-free interval (TFI) is currently unclear. The aims of this study were to assess if (1) a TFI is associated with a better HRQL vs. other treatment phases and (2) the length of the TFI influences HRQL.
View next paperComparative Effectiveness of Chemotherapy in Elderly Patients with Metastatic Colorectal Cancer